To:       Director of IHS Maternal & Child Health Program  
          IHS Area Chief Medical Officers  
          IHS Area Immunization Coordinators  
          Tribal Epidemiology Centers  

From:  Amy Groom, IHS Immunization Program Manager  

Date:  November 30, 2010  

The Indian Health Service, Tribal and Urban Indian immunization programs report on the immunization status of American Indian and Alaska Native (AI/AN) children 3-27 months of age, 19 – 35 months of age, and AI/AN adolescents 13 – 17 years of age. These reports are submitted to the IHS Division of Epidemiology and Disease Prevention on a quarterly basis.

### 3-27 Month Old Report

The 3 – 27 month report is designed to help programs ensure timely vaccination and identify children who may be falling behind so they can be brought up to date. The criteria listed below are used to monitor coverage in the following age groups:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Vaccines</th>
<th>Age Group</th>
<th>Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-4 months</td>
<td>DTAP1, IPV 1, Hib 1, Hepatitis B 1, (PNE1)†, (ROTA1)†</td>
<td>16-18 months</td>
<td>DTAP 3, IPV 2, MMR 1, Hib 3, Hepatitis B 2, (Varicella)†, (PNE4)†, (ROTA3)†</td>
</tr>
<tr>
<td>5-6 Months</td>
<td>DTAP 2, IPV 2, Hib 2, Hepatitis B 2, (PNE2)†, (ROTA2)†</td>
<td>19-23 months</td>
<td>DTAP 4, IPV 3, MMR 1, Hib 3, Hepatitis B 3, (Varicella)†, (PNE4)†, (ROTA3)†</td>
</tr>
<tr>
<td>7-15 months</td>
<td>DTAP 3, IPV 2, Hib 2, Hepatitis B 2, (PNE3)†, (ROTA3)†</td>
<td>24-27 months</td>
<td>DTAP 4, IPV 3, MMR 1, Hib 3, Hepatitis B 3, (Hepatitis A1)†, (Varicella)†, (PNE4)†, (ROTA3)†</td>
</tr>
</tbody>
</table>

† Not included in Age appropriate immunization coverage calculations

Pneumococcal conjugate vaccine (PNE), rotavirus vaccine (ROTA), varicella vaccine (VAR) and hepatitis A, though recommended, are not included in overall age appropriate coverage calculations. Data on PNE, ROTA, VAR and hepatitis A vaccine coverage are reported where available.
Summary

For FY 2010 Q4, 12 IHS Areas submitted immunization reports from IHS, Tribal, and Urban Indian health centers (I/T/U). This composite report provides information on the immunization status of 31,849 children 3-27 months old. Of these, 22,191 or 70% received all age-appropriate vaccinations compared to 71% (22,739/31,874) of children 3-27 months in the 3rd Quarter of FY 2010 [Figure 1]. Coverage by Area is included in the spreadsheet.

Figure 1

Age Appropriate Immunization Coverage
3 - 27 months
FY 2004 Q1 - FY 2010 Q4

[Graph showing age-appropriate coverage from FY 2004 Q1 to FY 2010 Q4]
The Two year old reports (children 19-35 months old) are used to monitor progress towards the GPRA childhood immunization indicator.

As of 2010, the 4:3:1:3:3:1 (4 DTaP, 3 IPV, 1 MMR, 3 Hib, 3 Hep B, 1 VAR) series is used to monitor coverage in this age group; the HP 2010 and GPRA goal is 80% with this series, and 90% coverage with each individual vaccine in the series.

4:3:1:3:3:1 Series
In FY 2010 Q4, 79% (19,029/23,958) of two year olds had completed the 4:3:1:3:3:1 vaccine series compared to 80% (19,512/24,388) in FY 2010 Q3 [Figure 3]. Coverage by Area is included in the spreadsheet.

Figure 2

4:3:1:3:3:1 Coverage
2 Year Olds
FY 2005 Q3 - FY 2010 Q4
IMPORTANT – CHANGES TO THE ADOLESCENT REPORT INCLUSION CRITERIA

The Adolescent Immunization Report was collected for the first time in FY 2008 Q1 and included adolescents manually deemed “active” by the facility. Starting with the FY 2010 Quarter 4 report, the adolescent report inclusion criteria changed and now include all adolescents meeting the electronically-determined “Active Clinical” user definition – i.e. 2 primary care visits in the last 3 years. Because of this change, in this and all future adolescent reports we will include data as of FY 2010 Q4 rather than FY 2008 Q1.

In general, the change in the report inclusion criteria resulted in an overall increase in the number of adolescents captured in the reports, and an overall decrease in coverage for most vaccines. In this report, we have included graphs comparing the FY 2010 Q2 and the FY 2010 Q4 data to illustrate the impact that the change in the inclusion criteria had on coverage.

This report collects data on adolescents 13 – 17 years and is designed to monitor uptake of “recently” recommended adolescent vaccines (e.g. tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap], meningococcal conjugate [MCV4], and human papillomavirus [HPV] vaccines) and monitor coverage in the adolescent population with the following recommended childhood vaccines: 1 dose of Td or Tdap, 3 doses of hepatitis B, 2 doses of MMR, and 2 doses of Varicella/Hx of chickenpox. A summary of immunization coverage for 13 year olds and 13 –17 year olds with these vaccines is included below.

Immunization Coverage with Tdap and MCV4 for 13 year olds, Males and Females

For FY 2010 Q4 the 12 IHS Areas combined reported on 15,570 thirteen year olds. This represents an increase in the total number of patients captured in the report compared to FY 2010 Q2. The FY 2010 Q2 report used different inclusion criteria and contained 12,337 thirteen year olds.

For FY 2010 Q4 80% (12,445/15,570) received 1 dose of Tdap vaccine, 83% (12,978/15,570) received 1 dose of Tdap/Td vaccine and 71% (11,094/15,570) had received 1 dose of MCV4 vaccine. [Figure 4].

In FY 2010 Q4, coverage by Area ranged from 61% - 90% for Tdap, 63% - 93% for Tdap/Td, and 45% - 95% for MCV4. Coverage by Area is included in the spreadsheet.

Figure 3
Tdap, Tdap/Td, and MCV4 Coverage for 13 year olds
FY 2010 Q2* and FY 2010 Q4

* FY 2010 Q2 report used different inclusion criteria than the FY 2010 Q4 report. This graph is intended to illustrate the impact the change in the inclusion criteria had on coverage.
Immunization Coverage for 13 – 17 year olds, Males and Females

For FY 2010 Q4 the 12 IHS Areas combined reported on 81,137 13 – 17 year olds. This represents an increase in the total number of patients captured in the report compared to FY 2010 Q2 which used different inclusion criteria. The FY 2010 Q2 report included 61,080 13 – 17 year olds.

For FY 2010 Q4, 88% (71,000/81,137) received 3 doses of hepatitis B vaccine, 89% (72,223/81,137) received 2 doses of MMR vaccine, 75% (61,031/81,137) received 2 doses of Varicella vaccine or had a documented history of chickenpox, 74% (59,845/81,137) received 1 dose of Tdap vaccine, 86% (69,475/81,137) received 1 dose of Tdap or Td and 71% (57,344/81,137) received 1 dose of MCV4 vaccine. Coverage by Area is included in the spreadsheet. [Figure 5].

Figure 4

Immunization Coverage for 13 - 17 year olds
FY 2010 Q2* and FY 2010 Q4

* FY 2010 Q2 report used different inclusion criteria than the FY 2010 Q4 report. This graph is intended to illustrate the impact the change in the inclusion criteria had on coverage
HPV Coverage for 13 – 17 year olds, Females Only

For FY 2010 Q4 the 12 IHS Areas combined reported on 43,692 females 13 – 17 years of age. This represents an increase in the total # of patients captured in the report compared to FY 2010 Q2 which used different inclusion criteria. The FY 2010 Q2 report included 32,246 females 13-17 years.

For FY 2010 Q4, 64% (28,140/43,692) had received 1 dose of HPV, 52% (22,761/43,692) had received 2 doses of HPV and 38% (16,805/43,692) had received 3 doses of HPV. [Figure 6].

For FY 2010 Q4, Coverage by Area ranged from 39% - 93% for HPV1, 30% - 83% for HPV2, and 22% – 64% for HPV 3. Coverage by Area is included in the spreadsheet.

Figure 5

HPV Coverage for Females 13 - 17 years
FY 2010 Q2* and FY 2010 Q4

* FY 2010 Q2 report used different inclusion criteria than the FY 2010 Q4 report. This graph is intended to illustrate the impact the change in the inclusion criteria had on coverage.